Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Menopause01:28

Menopause

5.2K
Menopause, a natural biological process marking the end of a woman's fertility, typically occurs between the fifth and sixth decade of life. This phase is characterized by the exhaustion of the ovarian follicle pool, leading to less responsive ovaries despite the high levels of Follicle Stimulating Hormone (FSH) and Luteinizing Hormone (LH). The consequential decrease in estrogen production results in symptoms like hot flashes, heavy sweating, headaches, hair loss, muscle pains, vaginal...
5.2K
Diseases of the Liver and Gallbladder01:26

Diseases of the Liver and Gallbladder

2.3K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
2.3K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

257
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
257
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

337
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
337
Hormonal Regulation of the Menstrual Cycle01:22

Hormonal Regulation of the Menstrual Cycle

2.3K
The ovarian cycle regulates endometrial changes throughout a single menstrual cycle via the coordinated action of gonadotrophin-releasing hormone (GnRH) and gonadotrophins.
At puberty, GnRH begins a pulsatile release pattern, which triggers the anterior pituitary gland to secrete follicle-stimulating hormone (FSH) and luteinizing hormone (LH). The frequency and amplitude of GnRH pulses vary across the menstrual cycle, with faster pulses favoring LH release and slower pulses favoring FSH...
2.3K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

347
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
347

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Perinatal Management of Esophageal Varices.

Obstetrical & gynecological survey·2026
Same author

Perinatal Management of Hepatic Adenomas.

Obstetrical & gynecological survey·2025
Same author

Living Donation and Pregnancy-Related Complications: State of the Evidence and Call To Action for Improved Risk Assessment.

Clinical journal of the American Society of Nephrology : CJASN·2024
Same author

Risk of stillbirth in United States patients with diagnosed intrahepatic cholestasis of pregnancy.

American journal of obstetrics and gynecology·2023
Same author

Reproductive health and liver disease: a patient-friendly summary of the 2021 AASLD guidance.

Clinical liver disease·2023
Same author

Getting to the core of the matter: the importance of biopsy in an unusual case of acute liver failure.

Clinical liver disease·2023

Related Experiment Video

Updated: Apr 7, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K

Liver disease in menopause.

Carla W Brady1

  • 1Carla W Brady, Division of Gastroenterology, Duke University Medical Center, Durham, NC 27710, United States.

World Journal of Gastroenterology
|July 14, 2015
PubMed
Summary
This summary is machine-generated.

Menopause accelerates liver disease development due to estrogen deficiency, increasing risks of nonalcoholic fatty liver disease and liver cancer. Early detection and aggressive treatment in menopausal women are crucial to prevent liver failure.

Keywords:
AgingLiver diseaseMenopause

More Related Videos

Author Spotlight: Investigating the Relationship Between FSH and Pathophysiological Changes in Perimenopausal Women - Insights from a Mouse Model
05:32

Author Spotlight: Investigating the Relationship Between FSH and Pathophysiological Changes in Perimenopausal Women - Insights from a Mouse Model

Published on: August 11, 2023

2.7K
A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
14:26

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice

Published on: April 7, 2014

16.4K

Related Experiment Videos

Last Updated: Apr 7, 2026

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause
06:18

An In Vivo Estrogen Deficiency Mouse Model for Screening Exogenous Estrogen Treatments of Cardiovascular Dysfunction After Menopause

Published on: August 13, 2019

13.0K
Author Spotlight: Investigating the Relationship Between FSH and Pathophysiological Changes in Perimenopausal Women - Insights from a Mouse Model
05:32

Author Spotlight: Investigating the Relationship Between FSH and Pathophysiological Changes in Perimenopausal Women - Insights from a Mouse Model

Published on: August 11, 2023

2.7K
A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice
14:26

A Method to Study the Impact of Chemically-induced Ovarian Failure on Exercise Capacity and Cardiac Adaptation in Mice

Published on: April 7, 2014

16.4K

Area of Science:

  • Hepatology and endocrinology, focusing on the intersection of menopausal transition and liver health.

Background:

  • Menopause is characterized by estrogen deficiency, exacerbating age-related physiological changes.
  • These changes include mitochondrial dysfunction, cellular senescence, and impaired immune responses, creating a pro-oxidative stress environment.
  • Estrogen loss impacts the liver's antioxidant capacity and response to injury.

Discussion:

  • Estrogen deficiency increases susceptibility to liver pathologies like nonalcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC).
  • Accelerated liver fibrosis progression is observed, notably in hepatitis C virus (HCV) liver disease.
  • Menopausal changes disrupt the balance between antioxidant defense and oxidative stress, promoting liver damage.

Key Insights:

  • Menopause significantly alters liver function and disease susceptibility.
  • Key factors include mitochondrial dysfunction, senescence, and oxidative stress imbalance.
  • Increased risk for NAFLD, HCC, and accelerated fibrosis progression in menopausal women.

Outlook:

  • Heightened awareness of liver disease risk in perimenopausal and menopausal women is essential.
  • Timely and aggressive treatment strategies can mitigate disease progression.
  • Preventing progression to cirrhosis, liver cancer, and liver failure is a primary goal.